 phase II studi combin methotrex teniposid infus reinduct therapi relaps childhood acut lymphoblast leukemia pediatr oncolog group studi teniposid intracellular methotrex mtx polyglutam deriv vitro potenti therapeut index regimen mtx phase II studi children adolesc acut lymphoblast leukemia first second marrow relaps simultan sequenti continu infus mtx reinduct infus hour complet mtx infus sequenti group dosag plasma concentr level micron mtx micron total infus time hour signific toxic first patient schedul infus drug-rel death reduct infus durat reduc dose similar manag toxic examin bone marrow day therapi complet partial marrow remiss fourth patient aplast marrow day chemotherapi complet remiss CR day obviou clinic advantag infus schedul small sampl size definit conclus respons rate therapeut window patient refractori diseas need investig altern schedul concomit therapi drug combin